Literature DB >> 28547950

Increased Risk of Thai Childhood Acute Lymphoblastic Leukemia with the MiR196a2 T>C Polymorphism

Sarinthorn Rakmanee1, Samart Pakakasama, Suradej Hongeng, Sirima Sanguansin, Acharawan Thongmee, Wanida Pongstaporn.   

Abstract

Objectives: This study assessed associations of the miR196a2 (rs11614913) T>C polymorphism withsusceptibility to childhood acute lymphoblastic leukemia (ALL) and clinical outcomes. Materials and
Methods: Blood DNA samples from 104 childhood ALL patients and 180 healthy children were studied for the miR-196a2 (rs11614913) polymorphism using a polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) approach.
Results: The frequency of the miR-196a2 (rs11614913) T allele in controls was 0.51 compared with 0.33 in ALL cases. In this study, CC, TC heterozygote and CC/TC genotypes were significantly associated with increase childhood ALL susceptibility compared with the TT wild type (OR =4.321, 95% CI = 2.091-8.930 p=0.000, OR = 2.248, 95% CI =1.103-4.579, p=0.024, OR = 2.921, 95% CI = 1.504-5.673 p=0.001, respectively). However, the miR-196a2 (rs11614913) T>C polymorphism was not associated with demographic data or clinico-pathological data in ALL cases.
Conclusion: CC, TC and CC+TC genotypes of miR-196a2 (rs11614913) was significantly associated with increased susceptibility in Thai childhood ALL but not with clinical variables. Creative Commons Attribution License

Entities:  

Keywords:  Acute lymphoblastic leukemia; miRNA; 196a2; polymorphism

Year:  2017        PMID: 28547950      PMCID: PMC5494224          DOI: 10.22034/APJCP.2017.18.4.1117

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


Introduction

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. The long term survival rate of ALL is nearly 90% in developed countries (Tasian et al., 2015; Pui et al., 2016). However, in Thailand, the long term survival rate is lower (Wongmeerit et al., 2016). The pathogenesis of ALL includes environmental risk factors and genetic susceptibility (Deepa et al.,2015). MicroRNA (miRNA or miR), a noncoding RNA, is the novel epigenetic biomarkers. Previous studies have reported the role of miRNA in several biological process including cell proliferation, differentiation and apoptosis. (Bartel, 2004; Hwang and Mendell, 2006). Recently, it was found that the dysregulation of miRNA expression contributes to multistep processes of carcinogenesis (Jansson and Lund, 2012; Hayes et al., 2014). Single nucleotide polymorphisms (SNPs) in the miRNA gene region have effects on the function of miRNA and contribute to cancer susceptibility (Mishra et al., 2008). Recently, several studies have investigated the association of miR-196a2 (rs11614913) polymorphism with cancer susceptibility. (Srivastava K and Srivastava A, 2012; Ma et al., 2013). However, there are very few studies focus on the association of miR196-a2 (rs 11614913) polymorphism in childhood ALL. In Caucasian, there is no association between miR-196a2 (rs11614913) polymorphism and risk of childhood ALL (Trevino et al., 2009). However, this significant association was found in Chinese population (Tong N. et al., 2014). This research aims to investigate the association of miR-196a2 (rs 11614913) polymorphism and childhood ALL susceptibility in Thailand. Moreover, the association of miR-196a2 (rs 11614913) polymorphism and clinical outcomes was also studied.

Materials and Methods

Study Subjects

This research was 284 case-control study including 104 childhood ALL patients and 180 healthy cancer-free children at the Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Thailand. Patients were classified by risk-based assignment protocol (Smith et al., 1996), assessed by initial white blood cell counts, French- American-British morphology and lymphomatous disease. Moreover clinical and demographic data including age at diagnosis, sex, immunophenotype and chromosome abnormalities were retrospectively studied. This research was approved by the Ethics Committee, Faculty of Medicine Ramathibodi Hospital, Mahidol University and inform consent was obtained from all the participants.

DNA Extraction

Genomic DNA extraction from EDTA blood of 194 healthy controls and 107 ALL patients and extracted by salting-out method (Miller SA et al., 1988). DNA was quantitated by a measurement of nano drop spectrophotometer and kept at -20°C prior to use.

Genotyping of the miR-196a2 (rs11614913) (T>C) polymorphism

The single nucleotide polymorphism of miR-196a2 (rs11614913) (T>C) was performed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) analysis. Genotyping of miR-196a2 (rs11614913) (T>C) polymorphism was done using forward primer 5’ CCC-CTT-CCC-TTC-TCC-TCC-AGA-TA 3’ and reverse primer 5’ CGA-AAA-CCG-ACT-GAT-GTA-ACT-CCG 3’ as describe previously. (Shuma et al., 2015). DNA was amplified in 25 μL reaction mixture containing 100 ng of genomic DNA, 20 μM of each primer, 5 μL of 10 X PCR buffer with 1.5 mM MgCl2 and 1 unit of Taq (i-Taq, European Biotech network, Belgium). The PCR cycle was carried out in a Thermocycler (Bio-RAD, Hercules, CA, USA). The PCR conditions were the initial denaturation of 95° C for 5 minute followed by 35 cycles of 94° C for 35 second, 61° C for 35 second, and 72° C for 40 second, with a final elongation at 72° C for 5 minute. The PCR products were found to be 149 bp in length by electrophoresis on 2% agarose gel, stained with 0.5 µg/ml ethidium bromide and then visualized using the gel documentation.

Restriction fragment length polymorphism (RFLP)

PCR products were digested by MspI (NEB, UK). The product sizes were verified on 3% agarose gel electrophoresis stained with 0.5 µg/ml ethidium bromide and then visualized using the gel documentation. The product presented three different patterns: a single 149 bp fragment for the TT genotype; two fragments of 125 and 24 bp for the CC genotype; and three fragments of 149, 125 and 24 bp for the CT genotype, respectively.

Statistical analysis

Comparisons of genotypes between cases and controls group were analyzed by binary logistic regression analysis. The associations between the clinical data and the distribution of the miR-196a2 genotypes in ALL patients were calculated by Chi-square test. Crude odds ratios (OR) and 95% confidence intervals (CI) were also calculated. P values less that 0.05 were considered statistically significant. All of the statistical analysis using SPSS version 17.0 program (SPSS Inc., Chicago, USA).

Results

Characteristic of the study population

The demographic data of ALL cases and control subjects as well as clinical data of ALL patients are summarized in Table 1. There were 104 ALL cases and 180 cancer-free controls. The demographic data shown that there was no significant difference in the frequency of sex distribution between ALL cases and controls (p=0.193). There was significant difference in the frequency of age distribution between ALL cases and control (p=0.009). Among ALL patients, there were 101 cases with known immunophenotype including 12 cases with T- ALL (11.88%), 78 cases with Early pre-B ALL (77.23%), 10 cases with pre-B ALL (9.90%) and 1 case of Mixed cell type ALL. The data of treatment protocol collected in 91 cases including 41 cases (45.05%) of low risk, 41 cases (45.05%) of standard risk and 9 cases (9.90%) of high risk ALL.
Table 1

Frequency Distribution of Selected Variables in Cases and Controls

Demographic characteristicsALL (%) n=104Controls (%) n=180
Sex
 Males65 (62.50)98 (54.44)
 Females39 (37.50)82 (45.56)
Age at diagnosis
 < 6 years64 (61.54)137 (76.11)
 >6 years40 (38.46) 43 (23.89)
Immunophenotype (n=101)
 T cell12 (11.88)-
 Non T cell89 (88.12)-
 Early pre-B78 (87.64)-
 Pre-B10 (11.24)-
 Mixed 1 (1.12)-
Risk classification (n=91)
 low risk41 (45.05)-
 Standard risk41 (45.05)-
 High Risk 9 (9.90)-
Frequency Distribution of Selected Variables in Cases and Controls

Association between miR-196a2 (rs11614913) T>C polymorphism and the susceptibility of childhood ALL

The allele frequency of miR-196a2 T allele in control was 0.51 compared with 0.33 in ALL cases (Table 2). The frequencies of the miR-196a2 (rs 11614913) genotypes was 29.45% for TT, 43.33 % for CT and 27.22 % for CC in controls, whereas the data was 12.50%, for TT, 41.35% for CT and 46.15% for CC in ALL cases. There were significant differences between the distribution of genotype frequencies of miR-196a2 (rs11614913) between ALL cases and controls. It was found that miR-196a2 (rs11614913) variant CC, TC heterozygote and CC/TC genotypes were significantly associated with increase childhood ALL susceptibility compared with TT wild type.(OR =4.321, 95% CI = 2.091-8.930 p=0.000, OR = 2.248, 95% CI =1.103-4.579, p=0.024, OR = 2.921, 95% CI =, 1.504-5.673 p=0.001, respectively).
Table 2

MiR-196a2 T>C Genotypes Distribution and Allele Frequency in ALL And Controls

GenotypesALL (%) n=104Controls (%) n=180OR (95%CI)*p-value**
TT13 (12.50)53 (29.45)1.000 (Reference)
TC43 (41.35)78 (43.33)2.2480.024
CC48 (46.15)49 (27.22)4.3210
TC+CC91 (87.50)127 (70.55)2.9210.001
Allele frequency
MiR196a2 T allele0.330.51
MiR196a2 C allele0.670.49

Odds ratio and p-value were calculated by comparison of control and ALL for TC, CC and CC+CT versus TT;

significant at the 0.05 level of significance

MiR-196a2 T>C Genotypes Distribution and Allele Frequency in ALL And Controls Odds ratio and p-value were calculated by comparison of control and ALL for TC, CC and CC+CT versus TT; significant at the 0.05 level of significance

Association between genotypes of the miR-196a2 (rs11614913) T>C polymorphism and clinicopathological data in childhood ALL patients

In this study, there was no association between miR-196a2 (rs11614913) T>C polymorphism and clinical data including gender, age at diagnosis, initial WBC count, immunophenotype and risk classification of ALL patients (Table 3).
Table 3

The Association between MiR196a2 T>C Genotypes and Clinico-Pathological Data of ALL Patients

Demographic dataMiR-196a2p-value
T/TCT or CC
Sex (n=104)
 Male9560.592
 Female435
Age at diagnosis (n=104)
 < 6 years7570.542
 >6 years634
Initial WBC count (n=97)
 <50,000 cell /µl6730.625
 >50,000 cell /µl216
Immunophenotype (n=101)
 T cell2100.676
 Non T cell1178
 Early –pre-B1068
 Pre-B19
 Mixed01
Risk classification (n=91)
 High Risk270.399*
 Low risk or Standard risk1072
 Low risk536
 Standard risk536

, p-value were calculated by comparison of genotypes between high risk and low risk or standard risk

The Association between MiR196a2 T>C Genotypes and Clinico-Pathological Data of ALL Patients , p-value were calculated by comparison of genotypes between high risk and low risk or standard risk

Discussion

MiRNAs are non coding RNA that inhibit the expression of protein coding genes by either mRNA degradation or translational repression. MiRNAs regulate cell proliferation, differentiation and apoptosis. Polymorphism of miRNA precursor may affect mature microRNA function (Ryan BM et al., 2010). Recently, several investigators study the association of miR-196a2 (rs11614913) polymorphism and cancer susceptibility. It was found that miR-196a2 (rs11614913) T allele was significantly associated with decreased susceptibility to breast cancer in Caucasian (Hoffman, et al., 2009; Dai et al., 2016). In contrast, TT genotype of miR-196a2 (rs 11614913) was associated with an increased risk of gastric cancer in Chinese (Gu and Tu, 2016). Moreover, it was shown that CC genotype of miR-196a2 (rs 11614913) was significantly associated with oral squamous cell carcinoma in Indian (Sushma et al., 2015) and lung cancer in Chinese. (Tian et al., 2009 and Yuan et al., 2013). To evaluate the association between miR-196a2 (rs11614913) polymorphism and susceptibility to Thai childhood ALL, case-control study was investigated in Thai children whose frequency of gender match between cases and controls. However, there is significant difference of age distribution between cases and controls. The previous study shown that the major allele of miR-196a2 (rs11614913) is C allele in Caucasian population whereas it is T in Chinese population (Chen et al., 2011). In this study, we found that the major allele in our control group was T allele which was 29.45% compared with 35.2% in Chinese population (Tong N et al., 2014). There were significant differences in the distribution of miR-196a2 (rs11614913) genotypes between ALL cases and controls. The miR-196a2 (rs11614913) variant CC, TC heterozygote and CC/TC genotypes were significantly associated with increase childhood ALL susceptibility compared with TT wild type. The association of miR-196a2 (rs11614913) genotypes with susceptibility to Thai childhood ALL in this study is similar to Chinese study (Tong N et al., 2014). They revealed that TC heterozygote and CC/TC were associated with an increased risk of childhood ALL in Chinese. However, in this study, the frequencies of miR-196a2 (rs11614913) T>C polymorphism were not associated with demographic data and clinical outcomes in ALL cases. There are several target genes of miR-196a2. MiR-196a2 may regulate different genes in different cell type or under different condition in a specific cell type. Genotype-phenotype correlation analysis revealed that CC homozygote in miR-196a2 was associated with significantly increased miR-196a2 expression (Hu et al.,2008). Recently, it was found that the target genes of miR-196a2 are homeobox family of genes which is called Hox genes. They involve in hematopoietic cell growth and differentiation. There was some evidences revealed that HOXC8, which suppressed cell migration and metastasis, is the target gene of miR-196a2 (Tong N et al., 2014). Another possible target genes of miR-196a2 are LSP1 (lymphocyte specific protein 1) and GDF3 (Growth/ differentiation factor 3 precursor) (Hu et al.,2008). However, there is still no study about the target genes of miR-196a2 in ALL patients. Further study should be done to investigate the pathogenesis about the interaction pathway between miR-196a2 and its target genes in acute lymphoblastic leukemia. In conclusion, miR-196a2 (rs11614913) T>C polymorphism was significantly associated with susceptibility to Thai childhood ALL and was not significantly associated with clinico-pathological variables.

Conflict of interest

The study presented no conflict of interest.
  21 in total

1.  microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis.

Authors:  Aaron E Hoffman; Tongzhang Zheng; Chunhui Yi; Derek Leaderer; Joanne Weidhaas; Frank Slack; Yawei Zhang; Trupti Paranjape; Yong Zhu
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

Review 2.  MicroRNAs in cancer: biomarkers, functions and therapy.

Authors:  Josie Hayes; Pier Paolo Peruzzi; Sean Lawler
Journal:  Trends Mol Med       Date:  2014-07-12       Impact factor: 11.951

Review 3.  Biology of childhood acute lymphoblastic leukemia.

Authors:  Deepa Bhojwani; Jun J Yang; Ching-Hon Pui
Journal:  Pediatr Clin North Am       Date:  2015-02       Impact factor: 3.278

4.  Genetic Variation in MicroRNAs and Risk of Oral Squamous Cell Carcinoma in South Indian Population.

Authors:  P S Sushma; Kaiser Jamil; P Uday Kumar; U Satyanarayana; M Ramakrishna; B Triveni
Journal:  Asian Pac J Cancer Prev       Date:  2015

5.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

Authors:  M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

Review 6.  MicroRNA and cancer.

Authors:  Martin D Jansson; Anders H Lund
Journal:  Mol Oncol       Date:  2012-10-09       Impact factor: 6.603

7.  Trends in Survival of Childhood Cancers in a University Hospital, Northeast Thailand, 19932012.

Authors:  Phunnipit Wongmeerit; Krittika Suwanrungruang; Arunee Jetsrisuparb; Patcharee Komvilaisak; Surapon Wiangnon
Journal:  Asian Pac J Cancer Prev       Date:  2016

8.  Effects of common polymorphism rs11614913 in Hsa-miR-196a2 on lung cancer risk.

Authors:  Zhengrong Yuan; Xu Zeng; Dan Yang; Weilu Wang; Zhihua Liu
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

Review 9.  MicroRNAs in cell proliferation, cell death, and tumorigenesis.

Authors:  H-W Hwang; J T Mendell
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

10.  Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies.

Authors:  Xiao Pin Ma; Ting Zhang; Bo Peng; Long Yu; De Ke Jiang
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more
  7 in total

1.  Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging.

Authors:  Tingting Liu; Guang Cheng; Xiaowei Kang; Yibin Xi; Yuanqiang Zhu; Kai Wang; Chao Sun; Jing Ye; Ping Li; Hong Yin
Journal:  Neuroradiology       Date:  2018-05-18       Impact factor: 2.804

2.  Polymorphisms in miRNA genes play roles in the initiation and development of cervical cancer.

Authors:  Zhiling Yan; Ziyun Zhou; Chuanyin Li; Xielang Yang; Longyu Yang; Shuying Dai; Jiehan Zhao; Huijing Ni; Li Shi; Yufeng Yao
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

3.  The miRNA 196a2 rs11614913 variant has prognostic impact on Turkish patients with multiple myeloma.

Authors:  Melya Pelin Kirik; Mustafa Pehlivan; Ayse Feyda Nursal; Yasemin Oyaci; Sacide Pehlivan; Istemi Serin
Journal:  BMC Res Notes       Date:  2020-11-23

4.  Association Analysis Between the Functional Single Nucleotide Variants in miR-146a, miR-196a-2, miR-499a, and miR-612 With Acute Lymphoblastic Leukemia.

Authors:  Silvia Jiménez-Morales; Juan Carlos Núñez-Enríquez; Jazmín Cruz-Islas; Vilma Carolina Bekker-Méndez; Elva Jiménez-Hernández; Aurora Medina-Sanson; Irma Olarte-Carrillo; Adolfo Martínez-Tovar; Janet Flores-Lujano; Julian Ramírez-Bello; María Luisa Pérez-Saldívar; Jorge Alfonso Martín-Trejo; Héctor Pérez-Lorenzana; Raquel Amador-Sánchez; Felix Gustavo Mora-Ríos; José Gabriel Peñaloza-González; David Aldebarán Duarte-Rodríguez; José Refugio Torres-Nava; Juan Eduardo Flores-Bautista; Rosa Martha Espinosa-Elizondo; Pedro Francisco Román-Zepeda; Luz Victoria Flores-Villegas; Edna Liliana Tamez-Gómez; Víctor Hugo López-García; José Ramón Lara-Ramos; Juana Esther González-Ulivarri; Sofía Irene Martínez-Silva; Gilberto Espinoza-Anrubio; Carolina Almeida-Hernández; Rosario Ramírez-Colorado; Luis Hernández-Mora; Luis Ramiro García-López; Gabriela Adriana Cruz-Ojeda; Arturo Emilio Godoy-Esquivel; Iris Contreras-Hernández; Abraham Medina-Hernández; María Guadalupe López-Caballero; Norma Angélica Hernández-Pineda; Jorge Granados-Kraulles; María Adriana Rodríguez-Vázquez; Delfino Torres-Valle; Carlos Cortés-Reyes; Francisco Medrano-López; Jessica Arleet Pérez-Gómez; Annel Martínez-Ríos; Antonio Aguilar-De-Los-Santos; Berenice Serafin-Díaz; María de Lourdes Gutiérrez-Rivera; Laura Elizabeth Merino-Pasaye; Gilberto Vargas-Alarcón; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; Haydeé Rosas-Vargas; Alfredo Hidalgo-Miranda; Juan Manuel Mejía-Aranguré
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

5.  Effect of miR-196a2 rs11614913 Polymorphism on Cancer Susceptibility: Evidence From an Updated Meta-Analysis.

Authors:  Md Abdul Aziz; Tahmina Akter; Mohammad Safiqul Islam
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools.

Authors:  Ioannis Kyriakidis; Konstantinos Kyriakidis; Aspasia Tsezou
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

7.  Association of ARID5B Genetic Variants with Risk of Childhood B Cell Precursor Acute Lymphoblastic Leukaemia in Latvia

Authors:  Madara Kreile; Dmitrijs Rots; Agnese Zarina; Linda Rautiainen; Zelma Visnevska-Preciniece; Zhanna Kovalova; Linda Gailite
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.